NCT04320771View on ClinicalTrials.gov

Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight

PHASE1TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 2, 2017

Primary Completion Date

August 8, 2018

Study Completion Date

December 17, 2018

Conditions
Pharmacology, Clinical
Interventions
DRUG

Neladenoson bialanate (BAY 1067197)

10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174

Trial Locations (2)

24105

CRS Clinical-Research-Services Kiel GmbH, Kiel

81241

APEX GmbH, München

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT04320771 - Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight | Biotech Hunter | Biotech Hunter